Your browser doesn't support javascript.
loading
Evaluation of Fluctuations of BRAF Gene Expression and its Polymorphism at rs1267623 in Colorectal Cancer.
Norollahi, Seyedeh Elham; Babaei, Kosar; Vahidi, Sogand; Hosseini Motaz, Seyed Javad; Kalani Tarbeghan, Mahmoud; Khaleghipour, Mostafa; Asghari Gharakhyli, Elaheh; Mirhafez, Seyed Reza; Samadani, Ali Akbar.
Afiliación
  • Norollahi SE; Cancer Research Center and Department of Immunology, Semnan University of Medical Sciences, Semnan, Iran.
  • Babaei K; Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
  • Vahidi S; Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran and Clinical Research Development Unit of Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
  • Hosseini Motaz SJ; Gastroenterology Clinic of Dr. Hosseini Gastroenterology Clinic of Dr. Hosseini Neyshabur Iran.
  • Kalani Tarbeghan M; Gastroenterology Clinic of Dr. Hosseini, Neyshabur, Iran.
  • Khaleghipour M; Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
  • Asghari Gharakhyli E; Department of Microbiology, Gorgan Branch, Islamic Azad University, Gorgan, Iran.
  • Mirhafez SR; Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
  • Samadani AA; Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Microrna ; 2024 Jul 12.
Article en En | MEDLINE | ID: mdl-39005128
ABSTRACT

BACKGROUND:

Molecular markers in Colorectal Cancer (CRC) are needed for more ac-curate classification and personalized treatment. In this way, we investigated the effects of the BRAF gene on clinical outcomes of its expression fluctuations and its polymorphism at rs1267623 in CRC.

METHODS:

In this study, 36.36 percent of patients with CRC were women, and 63.63 percent were men. After the pathology department confirmed the tumor of the samples, the stage and grade of the tumor were determined according to the TNM system. Real-time PCR was used to check the expression of the BRAF gene in tumor and non-tumor tissues, and its polymorphism in rs1267623 was also checked using the Tetra-ARMs PCR technique.

RESULTS:

The expression of BRAF in tumor tissues was significantly higher than in non-tumoral tissues (P = 0.001), indicating an upregulation of BRAF gene expression in tumoral tissues. The user's text is empty. Furthermore, there was a significant correlation between BRAF expression and tumor stage (P = 0.001), as well as tumor grade (P = 0.003). However, no significant link was found between lymph node metastasis and distant metastasis of BRAF gene expression (P = 0.3). Additionally, no mutation was detected in the investigation of rs1267623 polymorphism.

CONCLUSION:

The BRAF gene was upregulated in tumoral tissues. Remarkably, no mutation was found in the rs1267623 polymorphism. As a result, this gene can be used as a biomarker in the diagnosis and treatment of CRC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Microrna Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Emiratos Árabes Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Microrna Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Emiratos Árabes Unidos